<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159507</url>
  </required_header>
  <id_info>
    <org_study_id>IO3-01</org_study_id>
    <nct_id>NCT03159507</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Index on Cellular Metabolism and Quality of Life</brief_title>
  <official_title>Effect of Omega-3 Index on Cellular Metabolism and Quality of Life Following the Administration of a Customized Dose of Omega-3 Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCF Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université du Québec à Rimouski</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SCF Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine whether personal optimization of the Omega-3 index improves cellular metabolism and
      quality of life (according to the SF-36 form).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single arm trial where each participant receives a personalized dose</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Omega-3 Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Achievement of an omega-3 index of 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular metabolism</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine whether the achievement of the optimal level of the omega-3 index results in an improvement in the white blood cell energy metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determine whether the achievement of the optimal level of the Omega-3 index results in an improvement in quality of life (according to Form SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and total cholesterol (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and triglycerides level (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and HDL-cholesterol (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and LDL-cholesterol (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and alanine aminotransferase (in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and aspartate aminotransferase (in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and Bilirubin (in µmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and Albumin (in g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and C-reactive protein (in mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and Apolipoprotin B (in mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte sedimentation rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and the erythrocyte sedimentation rate (in min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and the systolic blood pressure (in mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Confirm the link between the optimal omega-3 index and the diastolic blood pressure (in mm Hg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MAG-EPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAG-EPA softgel (500mg), daily dose between 1g and 3.5g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MAG-EPA</intervention_name>
    <description>Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.</description>
    <arm_group_label>MAG-EPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant aged 18 or over

          -  Available for the entire duration of the study and willing to participate on the basis
             of the information provided in the FIU duly read and signed.

        Exclusion Criteria:

          -  Allergy known to fish

          -  Pregnant women who breast-feed or test positive for pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Julie Landry, MSc</last_name>
    <role>Study Director</role>
    <affiliation>SCF Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Fortin, PhD</last_name>
    <phone>514 317-9347</phone>
    <email>sfortin@scfpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SCF Pharma</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5M 1J5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Fortin, PhD</last_name>
      <phone>514 317-9347</phone>
      <email>sfortin@scfpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega-3 Index</keyword>
  <keyword>Cellular metabolism</keyword>
  <keyword>EPA Monoglyceride</keyword>
  <keyword>Quality of life</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

